A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KYN-5356 in Healthy Subjects Aged 18 to 55 Years
Phase 1
Completed
- Conditions
- SchizophreniaCognitive Dysfunction
- Interventions
- Drug: placebo
- Registration Number
- NCT06225115
- Lead Sponsor
- Kynexis B.V.
- Brief Summary
This first-in-human clinical trial with a randomized, double-blind, placebo-controlled, dose-escalation study design is regarded as standard to test the safety, tolerability, and pharmacokinetics of KYN-5356.
The study comprises 3 parts:
Part 1: Single Ascending Dose study Part 2: Multiple Ascending Dose study Part 3: Food Effect study
The aim of Parts 1 and 2 of the study is to evaluate the safety and tolerability following single and multiple ascending doses of KYN-5356.
The secondary aim is to evaluate the pharmacokinetics (PK) of escalating single and multiple doses of KYN-5356. In Part 2, cerebrospinal fluid will be sampled to explore PK and pharmacodynamic effects of KYN-5356.
The potential effect of food intake on the disposition of KYN-5356 following a single oral dose will be evaluated in Part 3. Part 3 is an open-label, randomized, 2 period, 2 sequence design.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 72
Inclusion Criteria
- Subject understands the study procedures and agrees to participate by providing written informed consent prior to any study procedures.
- Subject is between 18 and 55 years of age (inclusive), on the date of signing the informed consent form.
- Subject has a body mass index between 18 and 30 kg/m2, inclusive.
- A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: Not a woman of childbearing potential or a woman of childbearing potential who agrees to follow the contraceptive guidance (highly effective birth control method) from Screening until end of the study. Note: Males should use appropriate contraceptive method from Screening until end of the study.
- Subject is judged to be in good health by the Principal Investigator based upon the results of a medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory safety tests.
- Subject is willing to adhere to the study requirements and restrictions.
Exclusion Criteria
- Subject has positive serology for HBsAg, HCV, or HIV, or history of hepatitis from any cause with the exception of hepatitis A that was resolved at least 3 months prior to first dosing of the Investigational Medicinal Product.
- Subject has any illness judged by the Principal Investigator as clinically significant, in the 3 months prior to first dosing of the Investigational Medicinal Product.
- Subject has a suicidality score of "yes" on item 4 or item 5 of the suicidal ideation section of the C-SSRS, if this ideation occurred in the past 6 months, or "yes" on any item of the suicidal behavior section, except for the "Non-Suicidal Self-Injurious Behavior" (item also included in the suicidal behavior section), if this behavior occurred in the past 2 years.
- Subject has a history or current sign or symptom of psychiatric or neurologic disease.
- Subject has a history of head trauma in the past year and/or current seizures.
- Subject is a smoker (use of tobacco products in the previous 3 months from Screening) or uses nicotine or nicotine-containing products and has a positive urine cotinine test at Screening or Admission.
- Subject has a history of alcohol and/or illicit drug abuse within 2 years of entry or has a positive screening test for alcohol and/or drugs of abuse at Screening or Admission.
- Subject consumes caffeine containing beverages exceeding 500 mg caffeine per day (5 cups of coffee) during the off-site days during the study.
- Subject has regular excessive consumption of alcohol within 6 months prior to Screening (7 drinks/week for females, 14 drinks/week for males where 1 drink = 150 mL of wine or 360 mL of beer or 45 mL of hard liquor).
- Subject has a history or current sign or symptom of a cardiovascular, renal, or metabolic bone disease or disease of bone remodeling, or any history of endocrine disease, including an abnormal laboratory result for pre-specified clinical laboratory safety parameters related to these conditions.
- Subject has a history or presence of clinically significant abnormalities detected on 12-lead ECG of either rhythm or conduction. A first-degree atrioventricular block will not be considered as a significant abnormality. Subject has QTcF > 450 ms (mean values per parameter will be considered) detected on the 12-lead ECG at Screening or Admission.
- Presence or sequelae of gastrointestinal, liver, kidney (creatinine clearance <85 mL/min, using the Cockcroft-Gault formula), or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs at Screening or Admission.
- Subject has a history of malignancy within the past 5 years prior to Screening with the exception of excised and curatively treated non-metastatic cell carcinoma of the skin which is considered cured with minimal risk of recurrence.
- Subject tests positive for SARS-CoV-2 at Admission.
- Additional exclusion criteria for subjects in the MAD Part in view of lumbar puncture for cerebrospinal fluid (CSF) sampling and the ERP assessment.
- Subject uses any prescription drugs, herbal supplements, within 4 weeks prior to initial dosing, and/or over-the-counter medication, dietary supplements (vitamins included) within 2 weeks prior to initial dosing, other than what is allowed per protocol.
- Subject received vaccination 1 month before admission or plans to receive vaccination during the study.
- Use of other investigational drugs/devices within 5 half-lives of the drug from enrollment (time of the subject signing the informed consent form), or within 30 days, whichever is longer.
- Donation or loss of 400 mL or more of blood within 8 weeks prior to initial dosing.
- Plasma donation (> 200 mL) within 7 days prior to first dosing.
- Resting vital signs at Screening (blood pressure > 140/90 mmHg, heart rate > 90 beats per minute, respiratory rate > 20 breaths per minute, and clinically significant elevated body temperature), or any clinically significant abnormalities in vital signs requiring intervention in the opinion of the Investigator. Up to 2 repeat measurements are permitted to confirm eligibility.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description SAD Cohort 3 KYN-5356 Single-Ascending Dose Cohort 3. Intervention: KYN-5356 C mg or placebo, single dose, oral tablet SAD Cohort 4 KYN-5356 Single-Ascending Dose Cohort 4. Intervention: KYN-5356 D mg or placebo, single dose, oral tablet SAD Cohort 5 KYN-5356 Single-Ascending Dose Cohort 5. Intervention: KYN-5356 E mg or placebo, single dose, oral tablet SAD Cohort 5 placebo Single-Ascending Dose Cohort 5. Intervention: KYN-5356 E mg or placebo, single dose, oral tablet MAD Cohort 3 placebo Multiple-Ascending Dose Cohort 3. Intervention: KYN-5356 I mg or placebo, oral tablets for 7 days Food Effect Cohort KYN-5356 Intervention: KYN-5356 J mg, single dose, oral tablets in fasted or fed state. SAD Cohort 1 KYN-5356 Single-Ascending Dose Cohort 1. Intervention: KYN-5356 A mg or placebo, single dose, oral tablet SAD Cohort 1 placebo Single-Ascending Dose Cohort 1. Intervention: KYN-5356 A mg or placebo, single dose, oral tablet SAD Cohort 2 KYN-5356 Single-Ascending Dose Cohort 2. Intervention: KYN-5356 B mg or placebo, single dose, oral tablet SAD Cohort 2 placebo Single-Ascending Dose Cohort 2. Intervention: KYN-5356 B mg or placebo, single dose, oral tablet SAD Cohort 3 placebo Single-Ascending Dose Cohort 3. Intervention: KYN-5356 C mg or placebo, single dose, oral tablet SAD Cohort 4 placebo Single-Ascending Dose Cohort 4. Intervention: KYN-5356 D mg or placebo, single dose, oral tablet MAD Cohort 1 KYN-5356 Multiple-Ascending Dose Cohort 1. Intervention: KYN-5356 G mg or placebo, oral tablets for 7 days MAD Cohort 1 placebo Multiple-Ascending Dose Cohort 1. Intervention: KYN-5356 G mg or placebo, oral tablets for 7 days MAD Cohort 2 KYN-5356 Multiple-Ascending Dose Cohort 2. Intervention: KYN-5356 H mg or placebo, oral tablets for 7 days MAD Cohort 2 placebo Multiple-Ascending Dose Cohort 2. Intervention: KYN-5356 H mg or placebo, oral tablets for 7 days MAD Cohort 3 KYN-5356 Multiple-Ascending Dose Cohort 3. Intervention: KYN-5356 I mg or placebo, oral tablets for 7 days
- Primary Outcome Measures
Name Time Method Treatment-Emergent Adverse Events Initiation of dosing through the last follow-up visit after the last dose, approximately 8 days in the MAD and 5 days after dosing in the SAD and the Food Effect parts of the study All cohorts
- Secondary Outcome Measures
Name Time Method PK parameters: Cmax [SAD] Baseline (predose) through 72 hours post dosing Maximum plasma concentration determined directly from the concentration-time profile. For each dose in SAD part.
PK parameters: tmax [SAD] Baseline (predose) through 72 hours post dosing Time of maximum plasma concentration determined directly from the concentration-time profile. For each dose in SAD part.
PK parameters: AUCinf [SAD] Baseline (predose) through 72 hours post dosing Area under the concentration-time curve from pre-dose (time 0) extrapolated to infinite time calculated using the linear-log trapezoidal rule. For each dose in SAD part.
PK parameters: Cmax on Day 1 [MAD] Baseline (predose) through 24 hours post first dosing Maximum plasma concentration determined directly from the concentration-time profile. For each dose in MAD part
PK parameters: tmax on Day 1 [MAD] Baseline (predose) through 24 hours post first dosing Time of maximum plasma concentration determined directly from the concentration-time profile. For each dose in MAD part.
PK parameters: Cmax,ss [MAD] Baseline (predose) through 96 hours post dosing on Day 7. Maximum observed plasma concentration during a dosing interval at steady state. For each dose in MAD part.
PK parameters: tmax,ss [MAD] Baseline (predose) through 96 hours post dosing on Day 7. Time of maximum plasma concentration determined directly from the concentration-time profile at steady state. For each dose in MAD part.
PK parameters: AUCtau on Days 1 and 7 [MAD] Baseline (predose) through 96 hours post dosing on Day 7. Area under the concentration-time curve over the dosing interval. For each dose in MAD part
PK parameters: AUCinf [MAD] Baseline (predose) through 96 hours post dosing on Day 7. Area under the concentration-time curve from pre-dose (time 0) extrapolated to infinite time calculated using the linear-log trapezoidal rule. For each dose in MAD part.
Trial Locations
- Locations (1)
Parexel Los Angeles Early Phase Clinical Unit
🇺🇸Glendale, California, United States